Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study

M. Maurer, A.M. Giménez-Arnau, V. Jain, A. Reich, C-E. Ortmann, P. Walsh,
S. Haemmerle

Poster

Remibrutinib, an oral, highly selective BTKi in development for CSU: Analysis of safety data from the completed Phase 2 studies in inflammatory immune-mediated diseases

A.M. Giménez-Arnau, T. Chitnis, M. Williams, L. Airas, S. Saini, M. Hide, G. Sussman, J. Nakahara, R. Bermel, T. Dörner, B. Loop, V. DeLasHeras, R. Willi, B.C. Kieseier,
S. Haemmerle, R. Siegel, B. Cenni, H. Wiendl, M. Maurer, X. Montalban, A. Zharkov

Oral presentation

Remibrutinib treatment improves itch, sleep and activity in chronic spontaneous urticaria patients: Phase 2b study results

A.M. Giménez-Arnau, C. Hsu, R. Snyder, L. Clore, V. Jain, K. Lheritier, P. Walsh,
S. Haemmerle, M. Wells, I. Nikolaev, M. Maurer

Poster

Remibrutinib (LOU064) treatment decreases disease activity in patients with chronic spontaneous urticaria: Post hoc analysis from the Phase 2b study

A.M. Giménez-Arnau, M. Maurer, R. Snyder, C-E. Ortmann, B. Suryawanshi,
I. Nikolaev, M. Kuruvilla, S. Haemmerle

Oral presentation

Remibrutinib provides fast and clinically important improvement of CSU disease activity: Post-hoc analysis from the Phase 2b study

M. Maurer, A.M. Giménez-Arnau, J. Jacobs, S. Savic, C-E. Ortmann, B. Suryawanshi, I. Nikolaev, M. Wells, S. Haemmerle

Oral presentation

Remibrutinib improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Results from a Phase 2b study

M. Maurer, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh,
I. Nikolaev, A.M. Giménez-Arnau

Poster

Urticaria Voices: The use of patient-reported outcome measures for monitoring chronic spontaneous urticaria in clinical practice

J.A. Bernstein, P. Laires, M-M. Balp, P. Saraswat, T. Raftery, J. McCarthy, M. Dricu,
T.A. Winders, K. Weller

Poster

Urticaria Voices: Patients’ perspective on the negative impact of chronic spontaneous urticaria on their lives as well as their treatment goals

K. Weller, P. Laires, M-M. Balp, T. Raftery, P. Saraswat, J. McCarthy, M. Dricu,
T.A. Winders, J.A. Bernstein

Poster

Urticaria Voices: Opportunity for greater shared treatment decision-making by leveraging the existing high-quality relationship between patients and physicians

T.A. Winders, P. Laires, M-M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Dricu,
J.A. Bernstein, K. Weller

Poster

Remission and relapse profiles in chronic urticaria using real-world data​

M-M. Balp, I. Pivneva, A. Danyliv, K. Chen, T. Cornwall , J. Signorovitch, D. Patil,
R.K. Kohli, T. Severin, W. Soong, A.M. Marsland

Poster

Burden of angioedema in patients with chronic spontaneous urticaria in EU5 and US

M-M. Balp, K. Krupsky, L. Balkaran. Bridget, S. Gupta, C. Lienhard, D. Patil, R.K. Kohli, F. Tétart, T. El-Shanawany, J. Reed

Poster

Burden of chronic spontaneous urticaria relative to psoriasis and atopic dermatitis in Japan

M-M. Balp, M. Hide, A. Uda, F. Maki, R.K. Kohli, S. Gupta, K. Krupsky, B.L. Balkaran

Poster

Characterization of chronic spontaneous urticaria among patients in EU5, US and Japan

M-M. Balp, K. Krupsky, B.L. Balkaran, S. Gupta, C. Lienhard, D. Patil, R.K. Kohli,
A. Uda, F. Maki, F. Tétart, T. El-Shanawany, J. Reed, M. Hide

Poster

Patient-reported symptom burden in chronic inducible urticaria: Post hoc analysis of baseline data from a Phase 3 clinical trial

D. Whalley, M-M. Balp, S. Yarr, M. Porter, A. Barve

Poster

All EADV presentations will be made available once the embargo is lifted